- WVE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
Wave Life Sciences (WVE) S-8Registration of securities for employees
Filed: 12 Nov 24, 8:09am
Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Wave Life Sciences Ltd.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Offering | Maximum Offering Price | Fee Rate | Amount of Registration Fee | |||||||
Equity | Ordinary Shares, no par value | 457(c) and 457(h) | 5,000,000 (2) | $14.365 | $71,825,000 | $0.00015310 | $10,996.41 | |||||||
Total Offering Amount | $71,825,000 | $10,996.41 | ||||||||||||
Total Fee Offsets | — | |||||||||||||
Net Fee Due | $10,996.41 |
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional ordinary shares, no par value (“Ordinary Shares”), of Wave Life Sciences Ltd. (the “Registrant”), which may be subject to grant or otherwise issuable after the operation of any anti-dilution and other provisions of the Registrant’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”). |
(2) | Represents an increase of 5,000,000 Ordinary Shares of the Registrant reserved for issuance under the 2021 Plan approved by the Registrant’s shareholders at the 2024 Annual General Meeting of Shareholders. |
(3) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2021 Plan are based on the average of the high and the low price of the Registrant’s Ordinary Shares as reported on The Nasdaq Global Market as of a date (November 6, 2024) within five business days prior to filing this Registration Statement. |